NatureAug 5, 2026

A collection of tumor-grown mini-organs reveals which cancer genes are needed for growth

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 7, 2026

Abstract

A total of 256 clinically annotated tumour organoids were derived from various cancer types, including colorectal and pancreatic cancers.

Tumour organoids are three-dimensional cultures that better reflect patient tumour diversity compared to traditional cancer cell lines.
Whole-genome and transcriptome sequencing were conducted on the organoids and matched patient samples to characterize genetic features.
Genome-wide CRISPR-Cas9 screens identified gene dependencies across 162 organoids, revealing both common and rare subtype markers.
Organoid-specific essential genes and targetable vulnerabilities were identified by analyzing pre- and post-treatment samples.
In colorectal cancer, differences in the effects of KRAS variant alleles on the EGFR-RAS-MAPK signaling pathway were observed.

Simplified

Cancer cell lines remain foundational for research and drug discovery, yet they incompletely capture tumour diversity, lack linked patient context, and have undergone adaptation to culture. Tumour organoids are three-dimensional cultures derived from patient tissue that offer a powerful complement to cell lines¹. Here we derived and characterized 256 clinically annotated tumour organoids directly from colorectal, oesophageal, ovarian, pancreatic and gastric cancers as renewable, genetically stable models. Extensive characterization of each model and matched patient tumour samples included whole-genome and transcriptome sequencing, and genome-wide CRISPR-Cas9 screens across 162 organoids mapped gene dependencies. Integrative analyses revealed genomic and clinical markers of dependency across common and rare subtypes, identified organoid-specific essential genes, and revealed targetable vulnerabilities following tumour evolution in paired pre- and post-treatment samples. In colorectal cancer, functional and pharmacological interrogation of the EGFR-RAS-MAPK axis uncovered differential effects of KRAS variant alleles. This open, publicly available resource provides a systematic map of gene dependencies in patient-derived organoids, expanding the model diversity and mechanistic insight needed to advance precision oncology.